Technology Review - Published By MIT
Advertisement

Off-the-Shelf Genetic Testing On Display

The emerging market of direct-to-consumer genetic testing gets down to business.

By Emily Singer

Tuesday, June 09, 2009

smaller text tool iconmedium text tool iconlarger text tool icon

Want to share your genome online with friends and family? Find out how well you metabolize B vitamins? Determine if you're genetically susceptible to forming blood clots on long flights? All of this is possible with a credit card and an Internet connection, thanks to the growing field of direct-to-consumer genetic testing, which aims to move genetic tests out of the doctor's office and into the hands of individuals.

Credit: Technology Review

The first annual Consumer Genetics Show, which started today in Boston, highlights some of what's available to today's consumer. A number of genomics startups have booths lined up along the conference hall, offering everything from genetic tests that give individuals insight into their heart health, nutritional requirements, and optimal weight-loss strategies to full genome sequences. Inside the hall, meanwhile, scientists, physicians, and entrepreneurs are grappling with some of the controversies that have grown along with the field. Foremost among these concerns: How good is the information delivered by these tests? How well can people understand the results? And how effectively can they help people manage their health?

To date, medical genetics has been largely limited to tests ordered by physicians for rare disorders triggered by defects in single genes, such as cystic fibrosis. But as the price of genetic technologies has plummeted--the cost of sequencing a genome has dropped 10,000-fold in the past four years--the possibilities for genetic testing have grown. Scientists have identified hundreds of genetic variations that can raise the risk of common diseases, such as diabetes and heart disease; point to particular ancestries; and even influence traits, such as height.

Story continues below


A number of companies offering direct-to-consumer genetic testing have cropped up in the past two years to capitalize on these advances, from 23andMe and Navigenics, which offer genome-wide scans to identify specific disease-linked genetic variations, to Knome, which offers whole-genome sequencing to the wealthy. Any doubts that personal genomics is making its way into the mainstream can be assuaged with a look at Interleukin genetics, a startup that sells genetic tests for heart-disease risk, B vitamin metabolism, and other factors through Amway, the direct-sales company. "With minimal advertising, these companies have captured the imagination of the public," says Robert Green, a neurologist at Boston University and one of the conference organizers. "The public is eager to know more about genetics."

Along with this burst in genetic knowledge, however, comes a number of concerns. Scientists question how useful the currently available information is in managing one's health. "The most important issues in consumer genomics are around consumer utility and whether the kind of information available right now is useful to consumers medically and personally, and whether it has any potential for harm, either through misleading people, misunderstanding, or false reassurance," says Green. At this point, nongenetic factors, such as family history, body mass index, and history of smoking, often provide a better predictor of disease risk than does genetics, he says.

Comments

  • There's more to it
    DTC marketing of genetic tests raises many more significant issues.  Besides the utility of whatever genetic information these companies provide and the ability of the consumer and/or the consumer's primary healthcare provider to make informed use of whatever data is provided, what about the quality of the data?  the quality of the testing done? the privacy of that data? the quality of whatever interpretative information the testing company provides?  Consumers cannot be expected to make an informed decision about the reliability and quality of the testing that is done.  With a few exceptions the FDA does not have oversight over these labs and tests.  There are many pitfalls and gaps in DTC marketing of genetic testing.  I believe Ms. Singer has not done a thorough enough job of raising all the issues - and this is symptomatic of what is occurring in this industry.  There are many significant issues, and consumers, the media, and healthcare providers need to be better informed about the gaps, pitfalls and risks.  This new era of genetic testing can be a huge benefit, but we as a society are not yet prepared to take full advantage of it.  Until then, buyer (and others) beware!
    Rate this comment: 12345

    bblankenship
    06/09/2009
    Posts:1
    Avg Rating:
    5/5

Log In

Forgot your password?     Register »
Advertisement

Videos

Malleable Maps, Artistic Robots and Bubble Interfaces
Technology Review January/February 2010

Current Issue

Security in the Ether
Information technology's next grand challenge will be to secure the cloud--and prove we can trust it.
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2010 Technology Review. All Rights Reserved.